Ruxolitinib treatment reduces monocytic superoxide radical formation without affecting hydrogen peroxide formation or systemic oxidative nucleoside damage in myelofibrosis
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Ruxolitinib treatment reduces monocytic superoxide radical formation without affecting hydrogen peroxide formation or systemic oxidative nucleoside damage in myelofibrosis
Authors
Keywords
-
Journal
LEUKEMIA & LYMPHOMA
Volume -, Issue -, Pages 1-9
Publisher
Informa UK Limited
Online
2019-02-21
DOI
10.1080/10428194.2019.1579323
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- IL-10+ regulatory B cells are enriched in cord blood and may protect against cGVHD after cord blood transplantation
- (2016) A. Sarvaria et al. BLOOD
- Myeloproliferative neoplasms and inflammation: whether to target the malignant clone or the inflammatory process or both
- (2016) S Koschmieder et al. LEUKEMIA
- Simvastatin and oxidative stress in humans: A randomized, double-blinded, placebo-controlled clinical trial
- (2016) Sanne Tofte Rasmussen et al. Redox Biology
- JAK1/2 inhibition impairs T cell functionin vitroand in patients with myeloproliferative neoplasms
- (2015) Sowmya Parampalli Yajnanarayana et al. BRITISH JOURNAL OF HAEMATOLOGY
- JAK inhibition induces silencing of T Helper cytokine secretion and a profound reduction in T regulatory cells
- (2015) Clodagh Keohane et al. BRITISH JOURNAL OF HAEMATOLOGY
- The germline mutations of theCHEK2gene are associated with an increased risk of polycythaemia vera
- (2015) Hanna Janiszewska et al. BRITISH JOURNAL OF HAEMATOLOGY
- JAK Inhibition Impairs NK Cell Function in Myeloproliferative Neoplasms
- (2015) Kathrin Schönberg et al. CANCER RESEARCH
- Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I
- (2015) S. Verstovsek et al. HAEMATOLOGICA
- Long-term treatment with oral N-acetylcysteine: Affects lung function but not sputum inflammation in cystic fibrosis subjects. A phase II randomized placebo-controlled trial
- (2015) C. Conrad et al. Journal of Cystic Fibrosis
- Ruxolitinib is manageable in patients with myelofibrosis and severe thrombocytopenia: a report on 12 Danish patients
- (2015) Mads Emil Bjørn et al. LEUKEMIA & LYMPHOMA
- Pathogenesis of Myeloproliferative Neoplasms: Role and Mechanisms of Chronic Inflammation
- (2015) Sylvie Hermouet et al. MEDIATORS OF INFLAMMATION
- Inflammation as a Keystone of Bone Marrow Stroma Alterations in Primary Myelofibrosis
- (2015) Christophe Desterke et al. MEDIATORS OF INFLAMMATION
- The Role of Reactive Oxygen Species in Myelofibrosis and Related Neoplasms
- (2015) Mads Emil Bjørn et al. MEDIATORS OF INFLAMMATION
- MPNs as Inflammatory Diseases: The Evidence, Consequences, and Perspectives
- (2015) Hans Carl Hasselbalch et al. MEDIATORS OF INFLAMMATION
- Oxidative Modification of miR-184 Enables It to Target Bcl-xL and Bcl-w
- (2015) Jian-Xun Wang et al. MOLECULAR CELL
- JAK2V617F mediates resistance to DNA damage-induced apoptosis by modulating FOXO3A localization and Bcl-xL deamidation
- (2015) J S Ahn et al. ONCOGENE
- Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I
- (2015) S. Verstovsek et al. HAEMATOLOGICA
- Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms
- (2014) P. Lundberg et al. BLOOD
- JAK2V617F+ myeloproliferative neoplasm clones evoke paracrine DNA damage to adjacent normal cells through secretion of lipocalin-2
- (2014) Y. Kagoya et al. BLOOD
- From Janus kinase 2 to calreticulin: the clinically relevant genomic landscape of myeloproliferative neoplasms
- (2014) M. Cazzola et al. BLOOD
- Does ruxolitinib improve survival of persons with MPN-associated myelofibrosis? Should it?
- (2014) G Barosi et al. LEUKEMIA
- Whole Blood Transcriptional Profiling Reveals Deregulation of Oxidative and Antioxidative Defence Genes in Myelofibrosis and Related Neoplasms. Potential Implications of Downregulation of Nrf2 for Genomic Instability and Disease Progression
- (2014) Hans Carl Hasselbalch et al. PLoS One
- Associations and prognostic interactions between circulating levels of hepcidin, ferritin and inflammatory cytokines in primary myelofibrosis
- (2013) Animesh Pardanani et al. AMERICAN JOURNAL OF HEMATOLOGY
- Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis
- (2013) F. Cervantes et al. BLOOD
- The role of cytokines in the initiation and progression of myelofibrosis
- (2013) Hans C. Hasselbalch CYTOKINE & GROWTH FACTOR REVIEWS
- A role for reactive oxygen species in JAK2 V617F myeloproliferative neoplasm progression
- (2013) C Marty et al. LEUKEMIA
- A role of NF-E2 in chronic inflammation and clonal evolution in essential thrombocythemia, polycythemia vera and myelofibrosis?
- (2013) Hans C. Hasselbalch LEUKEMIA RESEARCH
- N-acetylcysteine reduces disease activity by blocking mammalian target of rapamycin in T cells from systemic lupus erythematosus patients: A randomized, double-blind, placebo-controlled trial
- (2012) Zhi-Wei Lai et al. ARTHRITIS AND RHEUMATISM
- Perspectives on chronic inflammation in essential thrombocythemia, polycythemia vera, and myelofibrosis: is chronic inflammation a trigger and driver of clonal evolution and development of accelerated atherosclerosis and second cancer?
- (2012) H. C. Hasselbalch BLOOD
- Gene expression profiling with principal component analysis depicts the biological continuum from essential thrombocythemia over polycythemia vera to myelofibrosis
- (2012) Vibe Skov et al. EXPERIMENTAL HEMATOLOGY
- Molecular profiling of peripheral blood cells from patients with polycythemia vera and related neoplasms: Identification of deregulated genes of significance for inflammation and immune surveillance
- (2012) Vibe Skov et al. LEUKEMIA RESEARCH
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- The JAK2 46/1 haplotype: a marker of inappropriate myelomonocytic response to cytokine stimulation, leading to increased risk of inflammation, myeloid neoplasm, and impaired defense against infection?
- (2011) S. Hermouet et al. HAEMATOLOGICA
- A risk of essential thrombocythemia in carriers of constitutional CHEK2 gene mutations
- (2011) H. Janiszewska et al. HAEMATOLOGICA
- Circulating Interleukin (IL)-8, IL-2R, IL-12, and IL-15 Levels Are Independently Prognostic in Primary Myelofibrosis: A Comprehensive Cytokine Profiling Study
- (2011) Ayalew Tefferi et al. JOURNAL OF CLINICAL ONCOLOGY
- ROS-mediated amplification of AKT/mTOR signalling pathway leads to myeloproliferative syndrome in Foxo3−/− mice
- (2010) Safak Yalcin et al. EMBO JOURNAL
- Oxidative stress is increased in primary and post−polycythemia vera myelofibrosis
- (2010) Claudia Vener et al. EXPERIMENTAL HEMATOLOGY
- Inflammation and thrombosis in essential thrombocythemia and polycythemia vera: different role of C-reactive protein and pentraxin 3
- (2010) T. Barbui et al. HAEMATOLOGICA
- Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability
- (2009) F. Colotta et al. CARCINOGENESIS
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More